Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache
Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes…